Related Experiment Videos
Is it safe to use antidepressants after a stroke?
Liborio Rampello1, Giuseppe Battaglia, Rocco Raffaele
1Department of Neurosciences, University of Catania, Azienda Policlinico, via S. Sofia, 78 95123 Catania, Italy. rampello@unict.it
Expert Opinion on Drug Safety
|August 23, 2005
Summary
Selective serotonin re-uptake inhibitors (SSRIs) are effective first-line treatments for poststroke depression (PSD). Careful patient selection is crucial, considering safety, tolerability, and comorbidities for optimal antidepressant therapy after stroke.
Area of Science:
- Neurology
- Psychiatry
- Pharmacology
Background:
- Poststroke depression (PSD) is a significant complication following a stroke.
- Antidepressant use in PSD patients is influenced by safety, tolerability, and comorbidities.
Purpose of the Study:
- To review the literature on antidepressant use in poststroke depression.
- To evaluate the efficacy, safety, and tolerability of antidepressants for PSD.
Main Methods:
- Literature review of studies on antidepressant use after stroke.
- Analysis of safety, tolerability, and efficacy data for various antidepressant classes.
Main Results:
- Selective serotonin re-uptake inhibitors (SSRIs) demonstrate efficacy and a favorable safety profile for PSD.
- SSRIs are recommended as first-line treatment, with considerations for cardiovascular effects and drug interactions.
- Other antidepressants may be suitable for specific patient subgroups.
Conclusions:
- SSRIs are effective and generally well-tolerated first-line treatments for PSD.
- Individualized treatment selection based on patient clinical profiles is essential for optimizing PSD management.
- Further consideration of potential adverse effects and drug interactions is necessary.